Search results
Results from the WOW.Com Content Network
Management of ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) focuses on symptoms management, as no treatments that address the root cause of the illness are available. [1]: 29 Pacing, or regulating one's activities to avoid triggering worse symptoms, is the most common management strategy for post-exertional malaise.
The Canadian Consensus Criteria require "post exertional malaise and/or [post exertional] fatigue" instead. [21] [22] [23] [19] [24] On the other hand, the older Oxford Criteria lack any mention of PEM, [25] and the Fukuda Criteria consider it optional. Depending on the definition of ME/CFS used, PEM is present in 60 to 100% of ME/CFS patients.
According to Lopate, et al., methylprednisolone is a viable treatment for chronic inflammatory demyelinative polyneuropathy (which can also be treated with intravenous immunoglobulin). The authors also indicate that prednisone has greater adverse effects in such treatment, as opposed to intermittent (high-doses) of the aforementioned medication.
The fatigue must have lasted for 6 months or longer, and be present at least 50% of the time; Other symptoms are possible, such as muscle pain, mood problems, or sleep disturbance; Conditions known to cause severe fatigue and some mental conditions exclude a diagnosis. Post-infectious fatigue syndrome also requires evidence of a prior infection ...
The term post-infectious fatigue syndrome was initially proposed as a subset of "chronic fatigue syndrome" with a documented triggering infection, but might also be used as a synonym of ME/CFS or as a broader set of fatigue conditions after infection. [26] Many individuals with ME/CFS object to the term chronic fatigue syndrome. They consider ...
Symptoms of these disorders include: fatigue, pain, lack of balance, lack of feeling, lack of reflexes, and lack of sight and hearing, which result from muscle atrophy. Patients can also have high arched feet, hammer toes, foot drop, foot deformities, and scoliosis. These symptoms are a result of severe muscular weakness and atrophy.
Small fiber neuropathy is a condition characterized by severe pain. Symptoms typically begin in the feet or hands but can start in other parts of the body. Some people initially experience a more generalized, whole-body pain. The pain is often described as stabbing or burning, or abnormal skin sensations such as tingling or itchiness. In some ...
Vinca alkaloids induce sensorimotor neuropathy, decreased sensation, in the hands and feet. Symptoms of vinca alkaloids include muscle weakness, initial pain after receiving an infusion, and cramping. These symptoms usually appear within the first three months of treatment. Of the vinca alkaloids, the most neurotoxic drug is vincristine.